Introduction
Genetic modification of hematopoietic stem cells (HSCs) represents a big challenge for both basic research and clinical application. The biological properties of HSCs and their accessibility for ex vivo manipulation render them one of the most promising targets of gene therapy. 1, 2 By definition, HSCs have the potential to reconstitute the entire hematopoietic system when administered into myeloablated recipients. Pluripotent HSCs are able to self-renew in vivo as well as to undergo a stepwise differentiation giving rise to a hierarchy of progenitor populations, ultimately leading to the generation of mature cells of multiple lineages with diverse functions. 3, 4 Therefore, ex vivo stable gene transfer into HSCs followed by transplantation could result in the long-term, possibly lifelong, persistence of genetically modified HSCs in the recipient, providing a potential cure to a number of disorders affecting components of the hematopoietic system. 5 Multiple genetic and acquired diseases are now being considered as candidates for gene therapy targeting HSCs. These include inherited immunodeficiencies, hemoglobinopathies and thalassemias, lysosomal storage diseases, hemophilias, hematological malignancies, chemotherapy-induced myelosuppression and many more. 6, 7 Practically, any disease affecting the production or function of hematopoietic cell subsets, which can be treated by bone marrow transplantation, is amenable to treatment by gene therapy targeting HSCs. In addition, the potential plasticity of HSCs may broaden the range of diseases treated by gene transfer into HSCs beyond hematological disorders. 8 It is widely accepted that the development of appropriate gene transfer vehicles will determine the speed at which the clinical application of genetically modified HSCs will proceed. 9, 10 Gene transfer systems for most gene therapy applications targeting HSCs must meet two main requirements: (1) efficient nucleic acid delivery into HSCs and (2) persistent expression of the transgene. For the latter, both long-term maintenance of the vector and sustained transcription of the transgene are required. Persistence of transferred genes is essential for HSCs because they are cells with a high proliferating potential and most applications require expression of the therapeutic gene in the mature hematopoietic cells that will be produced after multiple rounds of cell division. Therefore, the ideal vector should persist into the nucleus of long-term repopulating cells and should ensure expression of the transgene for the entire lifespan of the cell and its progeny. In addition, it should not interfere with the host cell normal function and with the clonogenic and repopulating capacity of HSCs.
In this article, we focus on the more restricted field of nonviral gene transfer into HSCs. We address the strengths and weaknesses of nonviral gene transfer systems and the potential advantages that justify research toward their development. We discuss the achievements made so far in the fields of both delivery methods and plasmid design and we aim at providing some clues on the expectations that are likely to be met in the near future.
A brief presentation of the limitations imposed by viral vectors, which justify search for alternative systems, follows, as a ground for comparison with nonviral systems.
Viral gene transfer systems for HSCs: limitations and pitfalls
Vectors derived from a variety of viruses with diverse properties have been considered as gene transfer vehicles for HSCs: murine oncoretroviruses, mainly Moloney murine leukemia virus (MuLV), adenovirus, adenoassociated virus, herpes simplex virus (HSV), lentiviruses, such as human immunodeficiency virus 1 (HIV 1), spumaviruses, such as foamy virus, and others. All viruses have a cardinal characteristic in common, which is exploited in viral-vector design: their natural ability to deliver genetic material to cells. This is mediated by proteins of the viral envelope that interact with cell surface receptors. Currently, gene transfer applications in HSCs use almost exclusively recombinant viral vectors, mainly retroviral vectors derived from MuLV. 11 The properties of retroviruses that are exploited in gene therapy are their ability to efficiently transduce human cells and to integrate into chromosomes, thus conferring stable gene transfer.
However, important considerations, principally regarding biosafety issues, have arisen over time concerning the use of retroviral vectors for human gene therapy. Present research focuses on the exploitation of ways to surmount these problems, 12, 13 while, at the same time, alternative solutions, such as the exploitation of nonviral systems -which are the main focus of this review -are now becoming increasingly relevant. The main problems related to viral gene transfer have been reviewed elsewhere 9, 14, 15 and will only briefly be stated here.
Pathogenicity
Even though the development of the newest generations of vectors 16, 17 has significantly reduced the probability of generation of a replication-competent virus, the emergence of a pathogenic virus through recombination still remains a considerable concern.
Immunogenicity Viral proteins evoke specific immune responses that may cause problems especially in cases when a significant proportion of the human population have previously encountered the virus and may have evolved an immune response against viral antigens. This not only limits the possibility of repeated administration of the vector, but may also give rise to dramatic systemic inflammatory responses, like the one responsible for the death of one patient following adenoviral gene transfer for the treatment of ornithine transcarbamylase deficiency. 18, 19 Insertional mutagenesis This is the most important biosafety consideration related to retroviral gene transfer. Vector insertion in the host genome can promote cellular transformation through transcriptional upregulation of cellular protooncogenes by viral enhancers, inactivation of tumor suppressor genes that surround the site of insertion or gene disruption. [20] [21] [22] The initially theoretical risks of oncogenesis proved to be very realistic, following recent direct evidence that insertional mutagenesis can induce malignant cell transformation in mice and humans. 20, 22, 23 In a clinical phase I trial, patients with X-linked severe combined immunodeficiency (SCID-X1) received CD34 + HSCs transduced with a retroviral vector based on MuLV that carried the therapeutic transgene. With a latency of 3 years, two out of 10 boys treated developed T-cell acute lymphoblastic leukemia. The causative event was identified as the integration of the vector into a known T-cell oncogene, LMO2, resulting in its aberrant expression, driven by retrovirus enhancer activity on the LMO2 gene promoter. Until these serious adverse events emerged in a clinical setting, preclinical animal models had failed to predict this risk.
Uncontrollable expression -silencing of transgene
Retroviral vectors appear to integrate into host DNA in a largely random fashion, so that every different integration site is likely to have a particular effect on transcription of the transgene resulting in inconsistency of its expression. Furthermore, transgene silencing occurs over time, mainly through promoter inactivation that is mediated by epigenetic mechanisms like CpG methylation and histone deacetylation. [24] [25] [26] DNA methylation is related to, or even triggered by, integration. 25, 27 Silencing of the transgene may be promoted by the selective recognition and inactivation of particular sequences 28 and/or by properties (heterochromatin/ euchromatin) of a given integration site, a phenomenon resembling 'position-effect variegation' in Drosophila. 29, 30 Cellular defense mechanisms against tandem integrates are also involved in this process (copy-number-dependent gene silencing, also known as repeat-induced silencing or cosuppression). 25, 31 Requirement for active cell cycling Oncoretroviruses cannot transduce nondividing cells owing to the barrier imposed by the intact nuclear membrane. 32 The vast majority of primitive cells with repopulating capacity are quiescent and this is believed to account for the low transduction efficiencies of longterm repopulating cells that are obtained with oncoretroviral vectors. 33 Two strategies have been implemented to overcome cell cycle dependence. The first one is induction of selfrenewal ex vivo 34 and involves the search for culture conditions that promote self-renewing divisions rather than divisions leading to commitment and differentiation. However, it appears that, even when using optimized ex vivo conditions, namely culture media and combinations of cytokines that favor self-renewal, in vitro stimulation of HSCs is unequivocally associated with differentiation and irreversible lineage commitment. 35, 36 A second approach is the search for vectors capable of transducing nondividing cells. Viral vectors derived from HIV or other lentiviruses have the ability to transduce quiescent cells, as they possess a nuclear localization element. 37 However, transduction of the nondividing fraction of cells is still less efficient than transduction of dividing cells. Most importantly, safety issues regarding the possibility of generation of replication-competent lentivirus are a major concern.
Insert size limitations
Although the packaging capacity varies among different categories of viral vectors, retroviruses have, in general, a limited capacity.
Practical concerns
Scaling-up of viral vector production is a technically and economically demanding issue. The requirement for robust safety evaluations also adds to the costs of viral vector production conforming to good manufacturing practice (GMP).
Nonviral gene transfer systems for HSCs
Nonviral vectors have considerable advantages over viral vectors for clinical use. Plasmid vectors contain no proteins and have, thus, a low immunogenicity. They are less toxic, more cost-efficient, easier to scale-up and to quality-control. As nonviral vectors possess no host cell specificity, they have a very large range of tissues and organs as putative targets. Although plasmids have been used in basic research for a long time, only lately have they been considered as gene therapy vehicles. Nonviral systems targeting various cell types have recently been exploited in in vitro and in vivo gene therapy applications. 38, 39 However, use of nonviral systems to target HSCs has so far been very limited. Two main reasons may account for this. The first is that nonviral vectors, mainly plasmid vectors, consist of one nucleic acid molecule with no associated proteins ('naked DNA') and are, by themselves, very inefficient in delivering genetic material to cells. Therefore, they have to be combined with a gene delivery method that enables entry into cells. However, HSCs are regarded as cells that are notoriously difficult to transfect. 40 The second reason is that plasmids are usually rapidly lost from highly proliferating cells since they lack mitotic stability.
Recent technological advances in nonviral systems combined with the strong advantages they confer justify the need for accumulation of data concerning the potential of nonviral systems to transfer genes into HSCs. In the following paragraphs, we review the currently existing data from nonviral gene transfer applications in HSCs.
Since a nonviral gene transfer system is specified by two components, (1) the delivery method and (2) the nucleic acid (typically, plasmid DNA), these will be addressed here separately.
Delivery methods
Standard physicochemical methods used for cell transfection include chemical methods, such as cationic lipids and cationic polymers, and physical methods, like particle bombardment and electroporation.
Chemical methods. Synthetic macromolecules, such as cationic lipids and polymers, have been extensively used for the introduction of DNA into various cell types. 41, 42 Although the exact mechanism of this process is not understood in detail, it is based on the ability of cationic lipids to neutralize the negatively charged DNA and facilitate the formation of condensed lipid/DNA complexes. 43, 44 It has been proposed that lipid/DNA complexes, possessing an excess of positive charges, bind to the negatively charged cell membrane and are subsequently taken up by cells, principally through endocytosis. 45, 46 DNA transfer may also be mediated by liposome destabilization of the cell and/or endosome membrane. 47 Several compounds are currently commercially available that confer good results with various cell types. 48, 49 Cationic lipids have more recently been considered as vehicles for gene therapy. 50, 51 However, little and not very encouraging data exist about their performance with hematopoietic cells, especially with primary hematopoietic cells. [52] [53] [54] Extensive optimization of various parameters (lipid, DNA and cell concentration, media, duration of exposure of cells to lipid:DNA complexes, etc) as well as trials of different synthetic lipid compounds has not yielded promising results, and no stable gene transfer has been reported even when a self-replicating Epstein-Barr virus (EBV)-based plasmid was used. 54 Limiting steps in efficient liposome-mediated transfection could involve any stage, namely endocytosis of lipid/DNA complexes, nuclear translocation or expression of the transgene. Degradation of DNA by phagocytosis is another factor possibly responsible for the low transfection efficiency. The low transfectability of hematopoietic cells with cationic lipids seems to be at least partly due to their nonadherent state in culture, since cells growing in suspension are generally inefficient in DNA/liposome uptake, probably owing to a lesser binding of DNA particles to the cell surface. 55, 56 In agreement with this, adhesion of hematopoietic progenitor cells to stroma or fibroblast monolayers has been suggested to increase transfection efficiency. 57 However, others have proposed that enhancement of transgene expression rather than of gene delivery accounts for the observed improvement of transfection efficiency in adhesion-assisted lipofection of HSCs. 58, 59 In addition, there are data indicating the dependence of transfection efficiency on the cell cycle phase. 60 The poor transfection efficiency of primary HSCs obtained with liposomes cannot be attributed solely to their growth in suspension, since hematopoietic cell lines also cultured in suspension are much more readily transfected. Additional, as yet unidentified, factors must also play a role in this process.
Basic research providing an insight into the exact mechanisms rendering cells amenable to cationic lipidmediated transfection is likely to drive the future design of improved synthetic liposome formulations, which have also to be compatible with administration into human subjects.
Physical methods
Particle-mediated transfection. Particle-mediated transfection, also referred to as 'gene gun' or 'particle bombardment', is another method of DNA delivery to mammalian cells used in both in vivo and in vitro applications. [61] [62] [63] In this relatively novel technique, also termed biolistics, DNA is adsorbed onto gold particles and administered to cells by a particle gun.
Particle-mediated transfection could potentially serve certain gene transfer applications targeting HSCs; however, very limited data exist so far about its efficacy. 64, 65 Verma et al have reported stable transfection of cord Electroporation. Electroporation refers to the application of an electrical field that is believed to transiently permeabilize cell membranes via reversible formation of pores. 66, 67 DNA is driven across the destabilized membrane through electrophoretic and electro-osmotic forces. 68, 69 Electroporation is an efficient way to introduce genes into practically all kinds of cells, even into cells that are 'refractory' to transfection by chemical methods [70] [71] [72] and has been used lately for several gene transfer applications both ex vivo and in vivo. 73 There is substantial evidence that electroporation is an efficient and reproducible method for gene transfer into hematopoietic cell lines [74] [75] as well as primary hematopoietic progenitor cells [76] [77] [78] and their progeny.
76,79-81
Wu et al, 78, 79 using optimized conditions, achieved transfection rates as high as 2077% of colony-forming cells (CFCs) and 2275% of long-term culture-initiating cells (LTC-ICs) and 41713% of CFCs and 2574% of LTC-ICs when peripheral blood and umbilical cord blood was used as the source of CD34 + cells, respectively. Satoh et al achieved expression of adenosine deaminase (ADA) gene in 37-100% of CFCs by combining electroporation with an episomally replicating EBV-based plasmid vector. Electroporation has also been used to transfer siRNAs into murine bone marrow HSCs with an average efficiency of 80%. 82 In addition, it was demonstrated that electroporation does not adversely affect functional integrity and clonogenic ability of HSCs 76, 83 and that nonstimulated HSCs can also be efficiently transfected. 83, 84 Regarding the requirement for active cell cycling for efficient transfection via electroporation, existing data from cell synchronization experiments are controversial. 80, [85] [86] [87] Prestimulation of CD34 + cells with recombinant cytokines for various time intervals prior to electroporation has been shown to enhance transfection efficiency and this effect was attributed to the increase in the subpopulation of cells in S phase. 78, 83 However, others demonstrated that stimulated and unstimulated CD34 + cells are transfected with equal efficiencies. 84 In our hands, prestimulation did not increase transfection efficiency when electroporation of CD34 + cells was combined with an episomal vector. 88 We believe that this discrepancy among authors is accounted for by two factors. First, the use of different plasmid vehicles, since some cis-regulatory elements may allow some DNA vectors to be more efficiently transferred through the nuclear membrane than others. Second, the use of diverse electroporation conditions; more stringent electroporation parameters may result in permeabilization of both plasma and nuclear membranes. CD34 + cell viability after transfection by electroporation ranges in the literature from as high as 77% 78 to as low as 16%. 89 One reason for this variability among authors is the way of defining and assaying cell viability (cell counting before and after electroporation, Trypan blue exclusion, propidium iodide staining, evaluation of apoptosis, etc). Furthermore, variations in cell mortality can be accounted for by the nature of the introduced nucleic acid as well as by the quality of the plasmid DNA (pDNA) preparation. 90, 91 Cell toxicity caused by the electroporation procedure does not manifest as an instantaneous death during permeabilization but rather involves the postpulse period when membrane resealing takes place. 89, [92] [93] [94] It has been proposed that death of electroporated cells is due -at least in part -to triggering of apoptosis that is mainly caused by the uptake of exogenous DNA 89, [95] [96] [97] as well as to colloidal-osmotic swelling of cells. 98, 99 Within this context, inhibition of apoptotic cell death has been shown to significantly reduce cell mortality. 89 It must be pointed out, however, that, although electroporation is conceived by many as a 'violent' means of transfection, developments of equipment (eg square wave pulse generators, allowing for independent optimization of pulse amplitude and pulse duration) and optimization of protocols for transfection of mammalian cells permit efficient transfection to be combined with high rates of cell viability. 100 In general, means of increasing transfection efficiency (eg using higher voltage) almost inevitably raise the percentage of nonviable cells. However, in our experience, efficiencies up to 30% can be achieved with acceptable cell mortality rates. Strikingly, human primary CD34 + cells are relatively tolerant to electric forces and exhibit a significantly greater postelectroporation viability compared to other primary cells or cell lines. 101 One should also bear in mind that cell toxicity from electroporation is probably exaggerated in an in vitro setting and that less cell death would occur in vivo.
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The recent emergence of 'nucleofection' technology provides a more sophisticated technology optimized in the basis of different cell types. As the DNA is delivered into the nucleus, unstimulated CD34 + cells can be transfected using this technology with efficiencies up to 70%, equaling those of retroviral systems. Thus, nucleofection is expected to find use in an increasing number of applications targeting CD34 + cells in the near future. [102] [103] [104] In conclusion, electroporation seems at present to be the most effective method for plasmid DNA delivery to HSCs. Furthermore, it is a method free from biocontamination and immune reaction concerns, as well as simple, time-effective, inexpensive and highly reproducible.
Categories of nonviral vectors
DNA vectors, into which the nucleic acid sequence to be transferred is cloned, comprise conventional plasmids, replicating episomal vectors (REVs) dependent on expression of a viral protein and a relatively new type of vectors that are based on genetic elements from the human genome (Figure 1 ).
Common plasmids. Common expression vectors are unable to replicate in mammalian cells and are lost from the cells over cell division, 105 unless they become integrated into chromosomes. Integration of plasmids is a very rare event, occurring with a probability of 1/10 3 to 1/10 5 . 106, 107 Furthermore, common plasmids are very inefficiently transported to the nucleus and are mostly left in the cytoplasm and subsequently degraded. Integration of plasmids in very low copy numbers after electroporation has been reported in hematopoietic progenitor cell lines 77 and in primary hematopoietic progenitor cells.
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Genetic
Regarding the differences in the transcriptional properties of transgene integration sites resulting from transduction with a virus particle compared to transfection using a chemical or physical delivery method, data are controversial. Retroviral integration uses an integrase-catalyzed nonhomologous recombination process 108 and the generally held opinion is that it occurs at favorable sites in the genome yielding higher levels of expression than transgene integration mediated by nonviral means. 109 However, electroporation-mediated transgene integration has more recently been shown to yield results comparable to retroviral integration. 110, 111 Transiently maintained plasmids may be of value in gene therapy targeting mature post-mitotic cells that have a limited lifespan (eg dendritic precursor cells), but are generally not appropriate for gene therapy applications targeting HSCs. However, there are occasions where permanent genetic modification is unnecessary, even undesirable, since transient gene transfer vectors bear a built-in safety feature against unforeseen adverse consequences. These include applications where a short duration of transgene expression is required, like multidrug resistance 1 (MDR1) gene transfer to HSCs, in order to confer protection against toxic effects of chemotherapy in patients with malignant diseases 112 or suicide gene transfer for the destruction of cancer cells.
Vectors based on episomally replicating viruses. REVs have the property of persisting in the host nucleus as autonomously replicating genetic units without integrating into chromosomes. [113] [114] [115] Vectors of this category were initially developed through the exploitation of genetic elements derived from viruses that are normally extrachromosomally replicating in cells upon latent infection, such as EBV, human polyomavirus BK, bovine papilloma virus 1 (BPV-1), HSV and Simian virus 40 (SV40). 116 Among them, EBV-based episomal vectors are the most extensively studied.
REVs have been used in various applications for some time, [117] [118] [119] [120] but only lately have they been considered as gene transfer vectors for human gene therapy 121, 122 and have been tested in combination with several delivery methods in a variety of cells, [123] [124] [125] including cells of hematopoietic origin.
81,126-129 EBV-based vectors have been shown to confer high-level expression of marker genes in human lymphoma cell lines, which, however, declined after removal of the selection pressure. 129 An EBV-based episomal cosmid vector carrying the human b-globin gene was shown to maintain therapeutic levels of expression in the absence of selective pressure for at least 90 generations in K562 cells. The inclusion of bLCR minilocus in the cosmid construct prevented transgene silencing over time. 126 Satoh et al 81 reported successful transfer and expression of human ADA gene in human hematopoietic progenitor cells with colony-forming capacity within an EBV-based vector.
Owing to their nonintegrating status, REVs eliminate the risk of insertional mutagenesis and are not subject to alterations of transgene expression associated with integration. 130 Even if some random integration events unavoidably occur 131 despite the lack of a mechanism for integration into chromosomes, these are very rare, below the level of background genomic mutation, and are, therefore, unlikely to be a significant risk factor. REVs also have a large size capacity giving them the ability to carry inserts of genomic DNA including introns and cis-regulatory elements, which are essential for certain gene therapy applications requiring tightly controlled, cell-specific transgene expression. 132, 133 In addition, they confer higher transfection efficiency, 127, 134, 135 as well as higher levels of expression compared to common plasmids. 135 EBV-based episomal vectors bear the additional advantage that they replicate only once per cell cycle, in S phase, along with chromosomal DNA. 136, 137 The importance of controlled replication is that it ensures low rates of spontaneous mutation (less than 1/10 5 ) and recombination events, 119, 138 although rearrangements of these vectors have rarely been described. 139 Combination of EBV-based episomal vectors with mammalian origins of replication has given them a broader host cell permissiveness.
117,118,140
Figure 1 A schematic representation of the three main types of currently available plasmid vectors. From top to bottom: a conventional expression plasmid unable to self-replicate into mammalian cells unless it is integrated in the genome; an episomal vector based on genetic elements of EBV, namely the origin of replication of EBV (oriP) and the region coding for EBNA-1 protein; a latest type of episomal vector, carrying the SV40 origin of replication (SV40 ori) and a human chromosomal S/MAR.
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As there is no efficient packaging system for EBVbased vectors, nonviral methods of delivery have to be used, raising again the issue of efficient delivery to cells. 81, 141 Another major concern regarding all these vectors is the requirement for the in trans action of a protein of viral origin. Episomal persistence of EBVbased vectors is dependent on EBV nuclear antigen 1 (EBNA-1) protein, 136, 142, 143 whereas SV40-based vectors require large T-antigen expression. 144, 145 This imposes risks related to immunogenic and transforming properties of EBNA1. [146] [147] [148] Another concern is that EBV-based vectors, although they have a prolonged retention even without selection pressure, they are often lost from cells under nonselective conditions. 127, 129, 142, 149, 150 An additional drawback is that EBV-based vectors are able to replicate only in primates, eliminating the exploitation of rodent model systems for preclinical assessment.
140,151
Chromosome-based episomal vectors. The development of episomal vectors devoid of virally encoded proteins is a highly desired goal. Late progress has turned this prospect into a realistic possibility. Basic research toward the development of episomal vectors based on human chromosomal elements involves the generation of human artificial chromosomes and, only recently, the development of minimal systems of small circular episomes. 115 Mammalian artificial chromosomes. Various attempts have been made in the past years to construct vectors resembling naturally occurring chromosomes for gene transfer into higher eucaryotic cells. 114, 115, 152, 153 Important features of human artificial chromosomes are that they contain exclusively human genomic elements, they have an infinite cloning capacity and they are mitotically stable in the absence of selection.
Since the construction of the first artificial chromosome, 154 a number of artificial chromosomes have been used as gene transfer systems. [155] [156] [157] Problems in the use of minichromosomes derive from difficulties in manufacture, handling and delivery to target cells owing to their enormous size (a few megabase pairs), as well as to their tendency to rearrange. Not only have mammalian artificial chromosome (MAC) vectors now become available, but transfer of a MAC into human cord blood CD34 + cells with an efficiency of 2.5-4.0% has very recently been achieved. 158 This opens the way to a new gene transfer alternative for HSCs, although a series of challenging technical barriers still have to be surmounted.
Small circular vectors. An alternative approach
involves the generation of minimal systems through the exploitation of genetic elements that play a role in the maintenance of nuclear architecture. Genetic elements of the human genome with a known role in human chromosome higher structure include scaffold/matrix attachment regions (S/MARs), insulators and locus control regions (LCRs).
Recent insights into the role of S/MARs in mediating episomal retention and sustained expression of genetic elements cloned in cis allowed the development of a prototype of a small circular episomal vector that functions independently of virally encoded proteins. This vector, named pEPI, was generated from an SV40-based vector -containing the SV40 origin of replicationby replacement of the gene coding for large T-antigen with an S/MAR 159 deriving from the 5 0 -region of the human interferon b-gene. 160 This small vector's unique characteristics reside in its ability to function as a stable episome in the absence of large T-antigen, a property attributed to its S/MAR. It has been shown that pEPI is stably maintained in various human and rodent cell lines 88, 159, 161, 162 in a low copy number, for at least 100 generations in the absence of selection and that it is able to self-replicate in mammalian cells once per cell cycle. 161 It is believed that the function of pEPI as a stable episome relies on the ability of its S/MAR to recruit cellular factors that mediate both its mitotic stability and its episomal replication. Plasmid pEPI is specifically associated through the S/MAR with the nuclear matrix and the chromosome scaffold in vivo 163 presumably via scaffold attachment factor-A (SAF-A) 164 and this interaction enables its cosegregation with the chromosomes upon mitosis. Moreover, the S/MAR in pEPI likely interacts with other nuclear proteins that mediate helix destabilization (a function of large T-antigen in conventional SV40 ori-containing episomal vectors), allowing for the assembly of the replication machinery. Thus, in contrast to viral episomes, which encode the factors required for their function, pEPI exploits, through its S/MAR, factors provided by the host cell to ensure both functions required for its extrachromosomal maintenance: replication and segregation.
These unique properties of pEPI, providing increased biosafety, prompted us to investigate the potential of this plasmid to serve as a gene transfer vector for therapeutic applications in primary human cells. According to data generated by us and others, pEPI can function as a stable episome in human and murine hematopoietic progenitor cell lines. 88, 159, 161, 162 Furthermore, it confers long-term transgene expression in K562 cells, as well as in primary human fibroblasts. 88 Most importantly, nonstimulated cord blood CD34 + cells are efficiently transfected with pEPI by electroporation, whereas retention of the vector in an episomal state was observed in a significant percentage of semisolid colonies derived from the transfected cells, which also expressed the transgene. 88 Interestingly, in our hands, pEPI exhibited an overall performance that was very similar to that of an EBVbased episomal vector (Figure 2) . Therefore, pEPI is a new small episomal vector that shows great promise as a gene therapy vector, also for cells exhibiting a high proliferating potential, like hematopoietic progenitors and most likely HSCs.
The exploration of this small episome's properties in an in vivo setting, as well as of the way it exerts its functions, is an issue of great interest. A deeper understanding of the mechanisms through which S/MARs confer the properties of episomal replication and mitotic stability is likely to open new possibilities for the development of gene transfer vectors with increased efficacy and biosafety in the near future.
Advantages of nonviral gene transfer into HSCs
Taken together, the main advantages of nonviral gene transfer into HSCs include the following: Transfection of resting cells with nonviral systems is likely equally efficient than that of dividing cells. 52 This offers the opportunity to totally skip ex vivo culture of HSCs, minimizing the time from gene transfer to cell administration. This provides a substantial advantage over retroviral gene transfer, which requires prestimulation of cells with growth factors, which is well known to result in the gradual decline of pluripotency and repopulating potential of hematopoietic precursors. 35, 36, 165 Since episomal gene vectors do not apparently have a preference for dividing cells, transfection efficiency in the subpopulation of CD34 + cells that are resting may theoretically equal overall transfection efficiency. Thus, even an overall efficiency lower than that of viral vectors may be counteracted by the relative higher efficiency in quiescent cells, which are the actual targets of gene transfer, being the fraction of primitive hematopoietic cells with the capacity to repopulate the bone marrow of the transplant recipient.
Future challenges
Improvements of nonviral vector systems may be targeted toward several aspects that are limiting steps of nonviral gene transfer. These include factors affecting delivery, as well as features of the plasmid construct. Whereas delivery methods have known considerable technological advances in the recent years, the importance of the plasmid construct has been more recently realized.
DNA uptake by cells
Optimizing transfection methods toward achieving greater efficiency combined with improved cell viability will be a major target of future technological developments. Certainly, the delivery method must not have an influence on normal cell function and must not interfere with the clonogenic or repopulating capacity of hematopoietic precursors. Existing data suggest that physical methods, electroporation in particular, yield better results with HSCs. Furthermore, electroporation is a fast, easy, safe and robust method and is also amenable to application in closed cell culture systems for clinical protocols.
Intracellular fate of pDNA
The fate of pDNA following cell entry is influenced by factors dependent on the transfection method, such as endosomal uptake, by pDNA stability in the cytoplasm, and by the rate and efficiency of nuclear transport.
Following lipofection, a significant amount of endocytosed pDNA is retained in perinuclear endosomes. On the contrary, physical transfection methods bypass this obstacle since pDNA is directly administered into the cytoplasm or even the nucleus. In any case, a major obstacle is degradation of free pDNA released in the cytoplasm, by nucleases. 166 Degradation of exogenous DNA is likely to involve cellular defense mechanisms against exogenous DNA uptake. The development of vectors devoid of most viral sequences is likely to skip their recognition as exogenous DNA and the activation of defense mechanisms by the host cell.
Nuclear transport
The nuclear membrane is another barrier to efficient gene delivery. 47, 55 Simple diffusion is an inefficient means of DNA uptake by the nucleus. Whereas DNA viruses exploit the cell's nuclear import machinery, 167 naked pDNA has no means of nuclear entry.
Efforts to enhance nuclear transport of pDNA are focusing on the exploitation of signal-mediated nuclear import, through electrostatic binding of DNA to cationic nuclear localization signal (NLS)-containing proteins, 168 peptides 169 or lipids. 170 Binding of pDNA to karyophilic proteins has also been attempted. 171 On the other hand, EBV-based REVs exhibit an enhanced ability to localize in the cell nuclei compared to conventional plasmids. 135 Although the exact mechanism is not known, interaction of EBNA-1 with oriP seems to facilitate nuclear transfer of the vector and binding to the nuclear matrix. An alternative approach involves skipping of the need for nuclear transport by utilization of the biochemical apparatus that permits some viruses, such as poxviruses and Sendai virus, to persist and replicate in the cytoplasm. 172 A recombinant Sendai virus has recently been exploited to achieve highly efficient transfection (85.5%) of cord blood CD34 + cells without cytokine prestimulation. 173 Mitotic stability of pDNA in the nucleus Mitotic stability of plasmid DNA can be achieved either through episomal maintenance or through chromosomal integration by the use of transposon 174 or phage integrase. 175, 176 Episomal maintenance is the most ambitious goal concerning stable gene transfer. Controllable expression and lack of interference with the host cell's chromosomes are the major advantages. Existing episomal vectors may be far from perfect, but gaining of a better insight into cellular factors involved in mitotic stability and extrachromosomal replication is likely to permit advances toward the rationalization and conception of new episomally maintained self-replicating systems.
Transcriptional and post-transcriptional processing of exogenous DNA Promoter/enhancer elements, as well as other transcriptional regulatory elements, 177, 178 are important features of the plasmid vector. Widely used constitutive viral promoters such as the CMV immediate-early promoter and the SV40 early promoter are very often inactivated over time. [178] [179] [180] There is evidence that viral promoter inactivation is immune mediated 181, 182 and evoked by elements of the bacterial pDNA backbone. 183 Immune stimulation is provoked at least partly by unmethylated bacterial CpG motifs. 184, 185 It is also possible that CpG motifs in plasmid DNA are de novo methylated in mammalian cells possibly as a defense mechanism against bacterial pathogens. Immune reactions can also be provoked by other differences in the composition of pDNA synthesized in bacteria from DNA produced in mammalian cells. 182, 183, 186 This raises again the need to exploit human chromosomal sequences that could substitute for regulatory cis-elements of viral origin, allowing the development of vectors devoid of most heterologous nucleic acid sequences. These include the use of human constitutive or tissue-specific promoters 187, 188 as well as the elimination of CpG motifs in nonessential regions of the vector backbone. 189 Minicircles are a new form of supercoiled DNA molecules devoid of bacterial origins of replication and of antibiotic resistance genes and are consequently smaller and theoretically safer than standard plasmids. 190 Apart from human gene promoters, other cis-regulatory elements might be able to enhance transgene expression. S/MAR sequences have been ascribed with the property of enhancement of transcription. Additionally, S/MARs may prevent the methylation-dependent inactivation by acting as bordering elements/insulators of chromatin. Thus, exploitation of S/MARs may be able to assign to vectors sustained expression of the transcription unit in addition to stable maintenance.
Cellular hypersensitivity to exogenous DNA
This is commonly manifested as induction of programmed cell death and is mediated by immune mechanisms. 95, 191, 192 Apoptosis of transfected cells may partly account for decline of transgene expression over time.
In this aspect, the importance of pDNA manufacturing needs to be stressed. Production of pDNA of high quality requires adequate purification procedures that will remove any contaminants -such as cell wall residues, bacterial genomic DNA, RNA, proteins and lipopolysaccharides (LPS, endotoxins) -as well as undesired plasmid topologies (open circular or linear), so that pure supercoiled (covalently closed circular, ccc) pDNA is used for transfection. 193 Large-scale production of pDNA conforming to GMP is now available.
Concluding remarks
The development of both effective and safe gene delivery systems for gene transfer in human HSCs is essential for gene therapy applications targeting HSCs. Obviously, the ideal vector for HSC targeting does not currently exist. As a consequence of serious adverse event reports in 1999 and 2002, 18, 20 clinical trials using viral vectors were put on hold. Very recently, a press release issued by the French regulatory agency disclosed a third adverse event in the same clinical trial for SCID-X1, involving, like the previous two, a T-cell lymphoproliferative complication in a third patient.
Tight regulatory restrictions that have been enforced by the FDA on human gene therapy trials using viral vectors have led to an increasing interest toward the use of nonviral systems. Nonviral methods still face major obstacles. However, their strong advantages over viral vectors justify research toward the end of overcoming currently existing drawbacks to their use in clinical applications. Two main obstacles have to be surmounted before nonviral systems reach clinical trials. At first, highly efficient delivery, comparable to that of viral vectors, has to be achieved. Second, stable long-term maintenance has to be ensured. At present, the efficiency of nonviral gene transfer in HSCs is, in general, significantly lower than that of viral vectors. However, a lower efficiency may be acceptable under certain conditions provided that other significant advantages, mainly safety, are ensured.
Continuing improvements of nonviral gene transfer systems may allow them to challenge and possibly surpass the superiority of viral vectors. Future advances will probably convert theoretical benefits of nonviral vectors into realistic gene therapy strategies. With the advent of emerging new technologies, nonviral gene transfer is likely to be a useful tool in the future that will greatly contribute to turning gene therapy into both an effective and safe treatment option for patients suffering from hematopoietic disorders.
